While every discovery is inspired by the search for something new, the kind of discovery molecular imaging enables is different. Molecular imaging can discover a deeper truth; evidence of what is seen, and often not. The kind of truth that can transcend an individual to make a greater impact on all patients. This is known as a true discovery.

A true discovery is what you are after. You aspire to not only help change the lives of the patients you see every day, but to establish new standards. This is what makes molecular imaging so exciting. While lesion detection, low dose, fast scans and image resolution are important, molecular imaging is more than that. It's about guiding treatment, supporting patients with sensitive care and creating an environment for compelling research. It requires technology that couldn't have been designed without our understanding of what continuously challenges you.

Challenges such as improving survival rates for those afflicted with cancer, expanding the diagnostic capabilities of PET and working with a revenue-generating system that permits you to work toward your aspirations.

Meet Discovery MI. A PET/CT system conceptualized with lofty goals, equal only to your own. It was created to help you diagnose and stage disease earlier and better guide your treatment strategies. It was designed with the hope you can conduct more compelling research more often with more novel, faster decaying tracers; permitting you to push the boundaries of PET. And it was built with capabilities aimed to more economically support increased patient volumes so your facility doesn't need to sacrifice advanced clinical work to accelerate its research initiatives.

We understand these are the types of outcomes you want to achieve. Discovery MI was engineered to help you get there. By delivering what you need for meaningful insights, we look forward to your next true discovery - something we all need.

Quantitation helped establish PET/CT as a valuable clinical tool. It provided an important starting point to find and follow disease throughout the course of treatment, but it was limited by the technologies used to produce it. Now, consistent, accurate SUV measurements are possible with Q.SUV. The ‘Q’ is important. It signifies the SUV measurement was produced exclusively from our innovative PET image reconstruction technology, Q.Clear, which delivers not only up to a 2x improvement in PET quantitation accuracy (SUVmean), but also up to a 2x improvement in image quality (SNR). For this reason, Q.Clear is a critical component of Discovery MI.

Q.SUV is more than a starting point for clinical decisions. Because it is more accurate and consistent than conventional methods, it becomes more than a number, it becomes a tool for communication. As a result, it sharpens communication between radiologists, oncologists and patients. Be sure your SUV starts with a ‘Q’.



Grow patient volumes as referring physicians value the accurate, reproducible results and diagnostic confidence you deliver

More accurately assess treatment response to guide your treatment planning decisions with more accurate SUVs

Improve communication with improved quantitation

Minimal configuration with integrated technologies takes up the least amount of space possible
Minimal configuration with integrated technologies takes up the least amount of space possible

Your work is multifaceted. Not only do you work every day to impact the lives of your patients for the better, you are looking for insights that will have a greater impact on the lives of every patient. You may be correcting the course of treatment for a cancer patient one day and looking for a new clinical indication for a high count-rate tracer the next. We understand. It’s why, after collaborating with leading clinicians and institutions across the globe, we designed Discovery MI to give you the flexibility to balance the quest for true discoveries with great clinical work.

Perform advanced diagnostic scans with FDG, or pursue groundbreaking research with faster decaying tracers. Enhance your clinical excellence in oncology, or expand PET’s impact on neurology and cardiology and beyond. Discovery MI was designed with the breakthrough technology and advanced quantitative software you need to answer the simple question of, “What if?”.

What if you had a PET/CT system with enhanced capability? The capability to evaluate the patients you see today and explore your vision for what PET/CT can be tomorrow.

High resolution whole-body 18F-FDG scan demonstrating exceptional resolution in the spine and high image quality and lesion conspicuity in the right lung, enabling high diagnostic confidence in your PET/CT images.

Data acquired on an equivalent technology - SIGNA PET/MR.

High resolution brain image demonstrating clear differentiation of grey and white matter, as well as separation of gyri and sulci, to aid in diagnosis of neurological disorders such as epilepsy foci, dementia and metastatic disease.

Data acquired on an equivalent technology - SIGNA PET/MR.



Continue your efforts to diagnose and stage disease earlier with technology that detects smaller lesions1

Increase the number of successful CT scans of patients with metal implants, with Smart MAR

Expand your diagnostic service offerings

Enhance utilization of limited-access tracers, such as 68Ga, with the highest NEMA sensitivity of any TOF PET/CT system

Provide a more comfortable patient experience with short scan times


Conduct more compelling research, such as quantitative brain studies, facilitated by an expanded FOV

Pursue improvement of PET/CT practice guidelines to better reflect capabilities in imaging small nodules

Explore PET capabilities in cardiac imaging, leveraging high sensitivity and small lesion detectability1

Increase low-yield tracer capability with protocols that reduce dose by up to 50 percent without impacting image quality and small lesion detectability1

Minimal configuration with integrated technologies takes up the least amount of space possible
Minimal configuration with integrated technologies takes up the least amount of space possible

It takes a certain kind of mind to go in search of true discovery. A thoughtful mind. A mind like your own that looks for a way to have a lasting impact on the world around them. You, like us, dream of helping to change patient lives for the better and influencing the future of medicine. To push the boundaries of medicine beyond its daily practice.

Our purpose is to provide you with the important instruments you need. It’s why we built Discovery MI. We see it as much more than a new imaging product. We see it as a result of our partnership that empowers your goal of forming new pathways to the future of medicine.

1 Improved detectability as demonstrated in phantom testing.
2  In clinical practice, the use of ASiR-V may reduce CT patient dose depending on the clinical task, patient size,  anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine  the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD),  Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR-V and FBP.  The LCD measured in 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183,  The Phantom Laboratory), using model observer method.
3  Image quality as defined by low contrast detectability.
4  Compared to Discovery PET/CT 710.
5  Up to 20 kBq/ml.